The major focus of our lab is to understand the signaling between anti-apoptotic proteins and cyclin dependent kinases and combining their targeted actions for the improved therapeutic strategies to overcome apoptotic resistance in leukemia. Our lab is collaborating with a biotech based organization – Aurigene Drug Discovery and Development Technologies Bangalore and Prof Marina Konopleva at MD Anderson Cancer Centre, Houston to address the targeted approaches in leukemia. Monitoring of minimal residual disease (MRD) by molecular markers, identification of miRNA-mRNA network in AML and characterization of high-risk acute promyelocytic leukemia are other research aspects of the laboratory.
The survival of acute myeloid leukemia (AML) blasts is dependent on the mitochondrial ap… more
With the advent of targeted therapy using arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) very high cu… more
Cyclin-dependent kinases (CDKs) regulate cell cycle and cell proliferation. CDK inhibition is predominantly succ… more
Kumar R, Kuligina E, Sokolenko A, Siddiqui Q, Gardi N, Gupta S, Varma AK, Hasan SK (2021)
Kuligina ES, Sokolenko AP, Bizin IV, Romanko AA, Zagorodnev KA, Anisimova MO, Krylova DD, Anisimova EI, Mantseva MA, Varma AK, Hasan SK, Ni VI, Koloskov AV, Suspitsin EN, Venina AR, Aleksakhina SN, Sokolova TN, Milanoviæ AM, Schürmann P, Prokofyeva DS, Bermisheva MA, Khusnutdinova EK, Bogdanova N, Dörk T, Imyanitov EN (2020)
Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK (2020)
Hasan SK, Patkar NV, Rajamanickam D, Gokarn A, Lucena-Araujo AR, Tembhare P, Bagal B, Amare PK, Jain H, Gujral S, Sengar M, Subramanian PG, Khattry N